PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00742352
Verified August 2008 by Tel-Aviv Sourasky Medical Center. Recruitment status was: Not yet recruiting
The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
65 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Breast cancer patients at the Tel-Aviv Sourasky Medical Center Lung cancer patients at the Tel-Aviv Sourasky Medical Center
Women over the age of 65 diagnosed with metastatic breast cancer
Men over the age of 65 diagnosed with lung cancer
Patients under the age of 65
Patients diagnosed with chronic inflammatory disease or chronic infection
Patients taking steroids and NSAIDS on a regular basis